Mirum Pharmaceuticals Unveils Rare Liver Disease Data at EASL Congress 2026
Event summary
- Mirum Pharmaceuticals will present data at the EASL International Liver Congress 2026, May 27-30, in Barcelona.
- Key presentations include late-breaking data from Phase 2b VISTAS study of volixibat in PSC and Phase 2b AZURE-1 study of brelovitug in HDV.
- LIVMARLI® (maralixibat) data in PFIC and emerging data in intrahepatic cholestasis of pregnancy (ICP) will also be highlighted.
- Volixibat and brelovitug have received FDA Breakthrough Therapy designation for PBC and HDV, respectively.
The big picture
Mirum Pharmaceuticals is positioning itself as a leader in rare liver disease therapies through its robust pipeline and strategic focus on unmet needs. The EASL Congress 2026 presentations underscore the company's commitment to advancing therapies for conditions like PSC, HDV, and PFIC, where treatment options are limited. The data could bolster Mirum's standing in the rare disease space and attract potential partners or investors.
What we're watching
- Clinical Efficacy
- How the Phase 2b data for volixibat in PSC and brelovitug in HDV will influence regulatory pathways and market positioning.
- Market Expansion
- Whether Mirum can leverage these data to expand into new rare liver disease indications and geographies.
- Competitive Dynamics
- The pace at which competitors develop similar therapies for cholestatic liver diseases and hepatitis D.
Related topics